Is COPD Set to Affect 600M Globally?
-
By
November 13, 2024
-
3 min
-
1
Global burden of COPD anticipated to affect nearly 600 million patients by
-
2
COPD's financial toll: Costs of respiratory diseases in the European Union approximately €38.6 billion annually.
-
3
Proportion of cases in low-income regions caused by nonsmoking factors like biomass exposure and occupational inhalants is around 50%.
-
4
Introduction of new phenotypes—Pre-COPD and PRISm (Preserved Ratio Impaired Spirometry).
-
5
Two new therapies, ensifentrine and dupilumab, included in GOLD 2025 recommendations for treating COPD.
-
6
Central role of spirometry in COPD diagnosis and updated lower limit of normal (LLN) values.
-
7
Recommendations for cardiovascular risk assessments, imaging, and vaccinations in COPD management and prevention.
-
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 report highlights significant updates on the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD). It presents comprehensive data on the increasing burden of COPD, estimates its financial toll in various regions, defines COPD as a condition with chronic respiratory symptoms and airflow obstruction, introduces new phenotypes, and incorporates two new therapies, ensifentrine and dupilumab, into its recommendations for treating COPD. The report also emphasizes the central role of spirometry in COPD diagnosis, updates lower limit of normal (LLN) values, offers enhanced guidance on reference scores, includes cardiovascular risk assessments, recommends imaging for additional assessment, and advises vaccinations and considerations of environmental factors for COPD prevention.
-
1
Global burden of COPD anticipated to affect nearly 600 million patients by
-
2
COPD's financial toll: Costs of respiratory diseases in the European Union approximately €38.6 billion annually.
-
3
Proportion of cases in low-income regions caused by nonsmoking factors like biomass exposure and occupational inhalants is around 50%.
-
4
Introduction of new phenotypes—Pre-COPD and PRISm (Preserved Ratio Impaired Spirometry).
-
5
Two new therapies, ensifentrine and dupilumab, included in GOLD 2025 recommendations for treating COPD.
-
6
Central role of spirometry in COPD diagnosis and updated lower limit of normal (LLN) values.
-
7
Recommendations for cardiovascular risk assessments, imaging, and vaccinations in COPD management and prevention.
Listen Tab content
